tbuckley/cabot-search huggingface dataset:
Correction: World Health Organization Estimates of the Global and Regional Disease Burden of 22 Foodborne Bacterial, Protozoal, and Viral Diseases, 2010: A Data Synthesis
Authors: Martyn D. Kirk, Sara M. Pires, Robert E. Black, Marisa Caipo, John A. Crump, Brecht Devleesschauwer, Dörte Döpfer, Aamir Fazil, Christa L. Fischer-Walker, Tine Hald, Aron J. Hall, Karen H. Keddy, Robin J. Lake, Claudio F. Lanata, Paul R. Torgerson, Arie H. Havelaar, Frederick J. Angulo
Journal: PLoS Medicine (2015)

There is an error in the fourth paragraph of the Discussion, second sentence.The correct sentence is: If we consider the combined burden attributable to S. enterica from all invasive (including iNTS, Salmonella Typhi and Salmonella Paratyphi A) and diarrheal infections, there were an estimated 21.2 million (95% UI 12.8-35.8million) DALYs from all transmission sources and 8.76 million (95% UI 5.01-15.6 million) DALYs from contaminated food.
Estimating the Replication Rate of Hematopoietic Stem Cells in Non-Human Primates: A Test of Hayflick’s Hypothesis.
Authors: Bryan E. Shepherd, Hans-Peter Kiem, Cynthia E. Dunbar, Andre Larochelle, Robert E. Donahue, Ruth Seggewiss, Peter M. Lansdorp, Peter Guttorp, Janis L. Abkowitz
Journal: Blood (2005)
Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in EGFR- Mutant Non–Small Cell Lung Cancer
Authors: Emily R. York, Marileila Varella-Garcia, Tami J. Bang, Dara L. Aisner, D. Ross Camidge
Journal: Journal of Thoracic Oncology (2017)
Immune Mobilization with Direct In-Vivo Effector Response: Clinical Trial with Favorable Implications for Post-Transplant Outcome.
Authors: John M. Hill, Jia-Yan Wu, Susan M. Webber, Lynn D. Root, Elizabeth A. Kimtis, Idalina C. Williams, Marc S. Ernstoff, Zbigniew M. Szczepiorkowski, Charles L. Sentman, Kenneth R. Meehan
Journal: Blood (2007)
The Role of MSI2 Expression Levels on Outcome of MDS and AML Patients
Authors: Felicitas Thol, Michael Heuser, Claudia Winschel, Frederik Damm, Katharina Wagner, Gudrun Göhring, Brigitte Schlegelberger, Gesine Bug, Oliver G. Ottmann, Wolf-Karsten Hofmann, Jürgen Krauter, Arnold Ganser
Journal: Blood (2011)
Comparative Survival of Haploidentical and Matched Related Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
Authors: Chen Huan, Kai-Yan Liu, Xu Lan-ping, Liu Dai-hong, Yu-hong Chen, Han Wei, Zhang Xiao-hui, Wang Yu, Qin Ya-zhen, Liu Yan-rong, Xiao Jun Huang
Journal: Blood (2014)
The Combination of a Histone Deacetylase (HDAC) Inhibitor with the BCL-2 Inhibitor GX15-070 Has Synergistic Antileukemia Effect by Inducing Both Apoptotic and Autophagic Pathways.
Authors: Yue Wei, Tapan Kadia, Weigang Tong, Susan O’Brien, Jean Viallet, Guillermo Garcia-Manero
Journal: Blood (2008)
Effects of Hepatic Function on the Pharmacokinetics and Safety of Panobinostat in Patients with Advanced Cancer: A Phase I Study
Authors: Dagmar Hess, Nicole Hagner, Sally Clive, Hans Gelderblom, Eva Rossmann, Neeraj Agarwal, Maria Grazia Porro, Thomas Hengelage, Annie St-Pierre, Lucien Gazi, Jason Li, Margaret M. Woo, Sunil Sharma
Journal: Blood (2011)
FAS Promoter Polymorphism and Etiology and Outcome of Childhood Acute Myeloid Leukemia.
Authors: Parinda A. Mehta, Todd A. Alonzo, James S. Elliot, Robert B. Gerbing, Tiffany A. Wilke, John P. Perentesis, Beverly J. Lange, Stella M. Davies
Journal: Blood (2004)
BAG1 Overexpression Restrains the Anti-Apoptotic BCL2, MCL1 and HSP70 Proteins in Acute Myeloid Leukemia.
Authors: Sanja Aveic, Elena Manara, Benedetta Accordi, Riccardo Masetti, Andrea Pession, Franca Fagioli, Franco Locatelli, Martina Pigazzi, Giuseppe Basso
Journal: Blood (2012)
Abstract OT1-02-07: SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+ metastatic breast cancer
Authors: HS Rugo, MD Pegram, WJ Gradishar, J Cortes, G Curigliano, S Hong, JM Wigginton, RJ Lechleider, F Cardoso
Journal: Cancer Research (2017)

Abstract Background: Despite significant advances in targeted therapy, HER2+ metastatic breast cancer (MBC) remains incurable. Ideal treatment includes pertuzumab and trastuzumab in combination with a taxane in the first line setting, followed by ado-trastuzumab emtansine on progression. Optimal treatment regimens in the third and greater line of therapy are not defined, but continued anti-HER2 therapy is recommended. Margetuximab is a Fc-modified monoclonal antibody to HER2 that recognizes the same epitope on HER2 as does trastuzumab, with similar affinity. Margetuximab demonstrates increased affinity to the activating CD16A Fc-receptor found on NK cells and macrophages and decreased affinity to the inhibitory CD32B receptor compared to trastuzumab. In vitro studies showed enhanced antibody dependent cell-mediated cytotoxicity compared to trastuzumab. In a Phase 1 dose escalation and expansion trial, margetuximab showed single agent clinical activity against HER2+ tumors in patients previously treated with trastuzumab and other anti-HER2 agents. Methods: SOPHIA is a randomized, prospective study testing the hypothesis that margetuximab plus chemotherapy (CTX) is more effective than trastuzumab plus CTX in patients previously treated for HER2+ MBC. Sequential primary endpoints are centrally assessed progression free survival (PFS) and overall survival (OS). The study size of 530 patients is determined to have 80% power to detect a hazard ratio for OS of 0.75. Secondary endpoints are investigator assessed PFS and centrally assessed overall response rate. Eligibility includes prior treatment with trastuzumab, pertuzumab, and ado-trastuzumab emtansine; no more than 3 prior lines of therapy in the metastatic setting; prior demonstration of HER2+ status at a local reference laboratory; and absence of active brain metastases. Eligible patients are randomized 1:1 to receive CTX (physician's choice: capecitabine, eribulin, gemcitabine or vinorelbine) plus either margetuximab or trastuzumab until disease progression or toxicity. Antibody may be continued after stopping CTX in patients with responding or stable disease. Progress to date: The trial was initiated July 2015 and is ongoing in the US and Europe with planned expansion to Korea and Israel. ClinicalTrials.gov Identifier NCT02492711; Eudract 2015-000380-13. Citation Format: Rugo HS, Pegram MD, Gradishar WJ, Cortes J, Curigliano G, Hong S, Wigginton JM, Lechleider RJ, Cardoso F. SOPHIA: A phase 3, randomized study of margetuximab plus chemotherapy vs trastuzumab plus chemotherapy in the treatment of patients with HER2+ metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT1-02-07.
T-ALL and thymocytes: a message of noncoding RNAs
Authors: Annelynn Wallaert, Kaat Durinck, Tom Taghon, Pieter Van Vlierberghe, Frank Speleman
Journal: Journal of Hematology & Oncology (2017)

In the last decade, the role for noncoding RNAs in disease was clearly established, starting with microRNAs and later expanded towards long noncoding RNAs. This was also the case for T cell acute lymphoblastic leukemia, which is a malignant blood disorder arising from oncogenic events during normal T cell development in the thymus. By studying the transcriptomic profile of protein-coding genes, several oncogenic events leading to T cell acute lymphoblastic leukemia (T-ALL) could be identified. In recent years, it became apparent that several of these oncogenes function via microRNAs and long noncoding RNAs. In this review, we give a detailed overview of the studies that describe the noncoding RNAome in T-ALL oncogenesis and normal T cell development.
Jak2 Regulates Bcr-Abl In CD34+ Cells From Imatinib Mesylate-Resistant CML Patients.
Authors: Ajoy K. Samanta, Bastianella Perazzona, Sandip N. Chakraborty, Xiaoping Sun, Hardik Modi, Ravi Bhatia, Ralph B. Arlinghaus
Journal: Blood (2010)
Incidental 99mTc-HDP Uptake in a Dominant Thyroid Nodule on Bone Scan
Authors: Deepa Shetty, Grace Yung, Roberto Russo, Robert Mansberg
Journal: Clinical Nuclear Medicine (2017)

A 67-year-old woman was referred for a bone scan for evaluation of increasing serum alkaline phosphatase levels. Bone scan revealed no abnormal uptake in the skeleton. However, intense hypervascularity and delayed tracer uptake were incidentally identified in an enlarged right thyroid gland. A thyroid scintigraphy, contrast-enhanced CT of the neck, and sonographic evaluation of the abnormality were subsequently organized to characterize the lesion. An ultrasound-guided fine-needle aspiration revealed a benign follicular pattern (Bethesda II), and histopathology of the right hemithyroidectomy confirmed a dominant nodule within a nodular goiter.
A Multicenter Phase II Clinical Trial of Rituximab Combined with Bortezomib (VELCADE®) Therapy for Untreated “High Tumor Burden” Indolent Non-Hodgkin Lymphoma (NHL)
Authors: Andrew M. Evens, Mitchell R Smith, Izidore S Lossos, Borko Jovanovic, Adam Cohen, Jane N. Winter, Steven T. Rosen, Leo I. Gordon
Journal: Blood (2012)
Are Microarray-Derived Gene Expression Signatures Useful as a Routine Assay for Prognostic Evaluation of Acute Myeloid Leukemia Samples with Low Leukemic Blast Content ?.
Authors: Philippe Guardiola, Diane Lambert, Pascale Cornillet-Lefebvre, Anne Coutolleau, Laurence Baranger, Franck Genevieve, Isabelle Luquet, Annaelle Beucher, Marc Zandecki, Norbert Ifrah, Odile Blanchet
Journal: Blood (2010)
Contemporary national trends of prostate cancer screening among privately insured patients in the United States.
Authors: Simon P. Kim, Jeffrey Karnes, Cary Philip Gross, Neal J. Meropol, Holly K. Van Houten, Robert Abouassaly, Nilay D. Shah
Journal: Journal of Clinical Oncology (2015)

5065 Background: Little is known about the degree to which prostate cancer (PC) screening with prostate-specific antigen (PSA) testing has changed in the face of recent clinical research data and the Grade D against screening from the U.S. Preventive Services Task Force. We used a large private health insurance database to determine the national trends of PSA screening and to investigate which patient characteristics are associated with PSA testing. Methods: Using Optum Labs Data Warehouse, a large private health insurance claims database, we identified males age 40-80 years who underwent PC screening from 2008 to 2013. The primary outcome was use of PSA testing among a privately insured population-based cohort. Demographic covariates included age, census region, race, education level and household income range. The Charlson/Deyo comorbidity index was calculated to assess comorbidity burden. Rates were calculated based on member-years and reported per 1,000 member-years. Results: Among 11.6 million eligible enrollees, we identified 2.9 million (25%) men who underwent PSA screening from 2008 to 2013 ( > 800,000 screened per year). The majority of the screened population were white males, age 50-59 years residing in the Southern census region. The rate of men undergoing PSA screening remained stable from 190.4 per 1,000 member-years in 2008 to 196.4 in 2013 (p = 0.66). Among enrollees aged 50 to 74 years old, PSA screening rates were relatively stable. However, enrollees who were > 75 years old had a marked decrease in PSA screening from 201.5 to 124.1 per 1,000 member-years from 2008 to 2013 (p = 0.04). PSA screening rates did not vary by racial groups or geographic region over time. Conclusions: In this large population-based cohort of privately insured men, we found little effect of new data and change in clinical practice guidelines on the overall rate of PSA screening. However, older men ( > 75) showed a significant reduction in screening over time.
Second Allogeneic Hematopoietic Stem Cell Transplantation for Relapse of Malignant Disease: Retrospective Analysis of Outcome and Predictive Factors
Authors: Tapani Ruutu, Ronald Brand, Anja van Biezen, Vanderson Rocha, Anna Sureda, André Tichelli, Hermann Einsele, Giorgio Dini, Marco Bregni, Laurent Garderet, Jane Apperley, Alois Gratwohl, Dietger Niederwieser, Theo de Witte
Journal: Blood (2008)
Activation of Lysosomal Function and Reactive Oxygen Species Play Crucial Roles in SAR650984-Induced Direct Killing of Human Multiple Myeloma Cells with Mutated p53, Which Is Further Augmented By Pomalidomide
Authors: Hua Jiang, Chirag Acharya, Gang An Gang An, Xiaoyan Feng, Zhili Song, Guang Yang, Francisco Adrian, Lugui Qiu, Paul Richardson, Nikhil C. Munshi, Yu-Tzu Tai, Kenneth C Anderson
Journal: Blood (2015)
Deferasirox (Exjade®) Monotherapy Significantly Reduces Cardiac Iron Burden in Chronically Transfused β-Thalassemia Patients: An MRI T2* Study
Authors: John C Wood, Alexis A. Thompson, Carole Paley, Barinder Kang, Patricia Giardina, Paul Harmatz, Jodi Virkus, Thomas D Coates
Journal: Blood (2008)
Involved field irradiation compared with prophylactic nodal irradiation to unresectable esophageal carcinoma: A retrospective study.
Authors: Xiaoli Zhang, Minghuan LI, Li Kong, Jinming Yu
Journal: Journal of Clinical Oncology (2013)

e15180 Background: We retrospectively observed the failure patterns in patients of local advanced esophageal squamous cell carcinoma (ESCC) with involved field irradiation (IFI) or with intentional prophylactic nodal irradiation (PNI). Methods: The ESCC patients with unresectable lesion (length &gt;6 cm or T4 or obvious node metastasis) were retrospectively analyzed between 2003 and 2009. All the reviewed patients received 3D-CRT with cisplatin based chemotherapy. For the IFI cases, the GTV was defined as any visible esophageal lesion(GTVe) and clinical involved node(GTVn). The CTVe was defined as the GTVe plus a 3-4cm margin superior and inferior to the primary tumor and a 1.0 cm radial margin. CTVn was defined as the GTVn plus a 0.5cm radial margin. The PTV was defined as CTV plus a 1.0cm margin. For the PNI cases, the same margins outside the primary tumor as that in IFI, and the adjacent regional lymphatics was included in the CTV according to the different location of primary tumor. The prescribed dose to PTV in IFI group was 60-64 Gy in 6-7 weeks and to PNI group was 40-50GY in 4-5weeks followed by 10-20Gy to PTVe+n. Results: Thirty-six cases received IFI and 49 cases underwent PNI. There were no difference between IFI and PNI group in tumor length and nodal status. The clinical response rates were 94.4% and 97.9% in IFI and PNI group, respectively, and no statistical difference was found ( P=0.785).The patterns of first failure in IFI and PNI group were listed as follows:(1) involved field failure, 17/36 vs 34/49 , P=0.046; (2) prophylactic nodal failure, 10/36 vs 4/49 P=0.02; (3) out field of regional nodal failure, 8/36 vs 15/49 , P=0.464; (4) distant metastasis, 17/36 vs 26/49, P=0.663. The medium PFS were 8.5m vs 12.0m( P=0.602), and the median OS were 14.0m vs 16.0m ( P=0.924)in IFI and in PNI group, respectively, and no statistical difference was found. Conclusions: Chemo-radiotherapy with PNI for unresectable ESCC showed better prophylactic field control, but had no advantage over the IFI in LC, PFS and OS.The involved field failure and distant metastasis were the main causes of failure in both groups, which suggests that the prophylactic irradiation may be not necessary for this sub-group patients.
Multiple Secondary Genetic Events Inducing Histologic Progression (HP) of Non-MALT Marginal Zone Lymphoma (MZL): An Integrated Genomic Analysis of Genome-Wide Copy-Number-Changes (CNC) and Transcriptomic Data.
Authors: Lise Willems, Josette Briere, Mahatsangy Raharijaona, Benoit Ballester, Samuel Quentin, Roxane Legaie, Delphine Rolland, Thierry Jo Molina, Pauline Brice, Eric De Kerviler, Christian Gisselbrecht, Francoise Berger, Alexandra Traverse-glehen, Lucile Baseggio, Pascale Felman, Gilles Salles, Bertrand Coiffier, Jean Soulier, Remi Houlgatte, Catherine Thieblemont
Journal: Blood (2008)
Risk factors for thromboembolic events in testicular cancer patients receiving chemotherapy
Authors: K. Shim, K. R. Potvin, K. Mills, F. Whiston, L. Stitt, E. Winquist
Journal: Journal of Clinical Oncology (2009)

e16109 Background: Cancer patients are at increased risk for thromboembolic events (TTEs), and those receiving chemotherapy are at even greater risk. Clinical experience and the literature have suggested that men receiving cisplatin-based chemotherapy for metastatic germ cell tumors are at particularly high risk. As TTEs can be fatal and treatment is curative, the stakes are high. Despite this, prophylactic anticoagulation (PA) is not routinely used. Methods: All men treated with cisplatin-based chemotherapy for metastatic germ cell cancer at the London Regional Cancer Program from January 1978 to December 2007 were identified from electronic databases. Data including type and timing of TTEs were extracted by retrospective chart review. Multivariable analyses were used to identify predictors of TTEs. Results: 196 eligible patients were identified with median age 31 years (range, 15–75). No patients received PA. Thirty-two TTEs were identified in 29 patients for an overall incidence of 14.8% (95% CI, 9.8–19.8%). The majority of events were deep venous thromboses, and five patients died due to TTE or its complications. Sixteen of the patients with TTE (55.2%) were diagnosed while on treatment (defined as TTE within 6 months of chemotherapy initiation); 8 (27.6%) had their TTE prior to, and 5 (17.2%) after this time period. Age greater than 30 years (OR = 3.02; 95% CI, 1.10–8.33; p = 0.033) and elevated LDH (OR = 1.93; 95% CI, 1.07–3.48; p = 0.029) were independently associated with an increased risk of TTE. If both adverse risk factors were present, the risk of TTE on treatment was 21.7% (95% CI, 9.8–33.7%). If neither were present, the negative predictive value was 97% (95% CI, 92–100%). Conclusions: The overall TTE incidence rate of 14.8% is consistent with prior reports (8.4–19%). The risk of TTE appears greatest during chemotherapy and shortly thereafter, and nearly one in 10 patients in this group had a TTE. These data support the concept of PA for selected patients starting chemotherapy for metastatic germ cell cancer. However, the efficacy of PA and risk of hemorrhage in this group is unknown. In this cohort, patients under 30 with normal LDH were at very low risk for TTE. Confirmation of these findings to help guide the study and optimal use of PA should be pursued. No significant financial relationships to disclose.
Harvey Cushing, MD—A Neurosurgeon’s Contributions to Cutaneous Pathology
Authors: Jasmine Kashkoush, Ahmed Kashkoush, Arpan V. Prabhu, Thomas G. Benedek
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Abstract P5-03-04: To excise or not?: Scoring system for predicting malignancy in patients diagnosed with intraductal papilloma at ultrasound-guided core needle biopsy
Authors: Sk Ahn, H-G Moon, W Han, D-Y Noh, E Ko
Journal: Cancer Research (2017)

Abstract Background: The management of benign intraductal papillomas on core biopsy is controversial. The aim of this study was to determine factors that predict under-evaluation of atypical lesion or malignancy in patients diagnosed with benign papilloma at ultrasound-guided core needle biopsy (CNB), and to develop a prediction algorithm for scoring the possibility of a diagnosis upgrade to atypical lesion or malignancy based on clinical, radiological and pathological factors. Methods: The study enrolled patients diagnosed with benign papilloma at ultrasound-guided CNB who subsequently underwent surgical excision of the lesion. Multivariate analysis was used to identify relevant clinical, radiological and pathological factors that may predict malignancy. Results: A total of 520 CNBs led to a diagnosis of benign papilloma (including benign and atypical papillary lesion), of which 452 CNBs were benign papilloma without atypia. Of the 250 lesions in 234 women were underwent subsequent surgical excision, 44 (17.6%) were diagnosed with atypia or malignancy. Multivariate analysis revealed that bloody nipple discharge, size on imaging ≥15 mm, BIRADS≥4b, peripheral location, and a palpable lesion were independent predictors of atypical lesion or malignancy. A scoring system was developed based on logistic regression models and beta coefficients for each variable. The area under the ROC curve was 0.830 (95% CI: 0.665-0.996), and the negative predictive value was 100% for a score ≤4. Conclusions: A scoring system to predict malignancy in patients diagnosed with benign papilloma at CNB was developed based on five factors: bloody nipple discharge, size on imaging ≥15 mm, BIRADS≥4b, peripheral location, and a palpable lesion. This system was able to identify a subset of patients with lesions likely to be benign, indicating that imaging follow-up rather than surgical excision may be appropriate. Citation Format: Ahn Sk, Moon H-G, Han W, Noh D-Y, Ko E. To excise or not?: Scoring system for predicting malignancy in patients diagnosed with intraductal papilloma at ultrasound-guided core needle biopsy [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-03-04.
Descriptive Analysis of Bortezomib Use in Multiple Myeloma in Four Adult University Teaching Hospitals in Quebec, Canada
Authors: Nathalie Marcotte, Marie-Claude Michel, Louise Deschenes, Nathalie Letarte, Daniel Froment, Emilie Lemieux-Blanchard, France Varin, Ghislain Bérard, Paul Farand, Élaine Pelletier, Pierre Gaudreault, Chantal Guévremont, Raghu Rajan, Michael Sebag
Journal: Blood (2015)